Tokyo Tape
Sign in
← Trans Genic

Quarterly report · Q2

2342.TEDINET S100S7OP
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥6.4bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥11.4bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥5.5bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥89m2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥135m2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥95m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥199m2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥204m2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥94m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥157m2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥48m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥410m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥55m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥42m2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥55m2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥10.5bnat 2023-09-30Cons.Assets
Total assets¥10.7bnat 2023-03-31Cons.Assets
Total assets¥10.7bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥4.4bnat 2023-09-30Cons.Liabilities
Total liabilities¥4.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥6.1bnat 2023-09-30Cons.Net assets
Net assets / equity¥6.1bnat 2023-03-31Cons.Net assets
Net assets / equity¥6.6bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥2.9bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥3.5bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥2.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.5bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥4.6bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow−¥366m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥696m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥129m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥216m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥601m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥47m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥485m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥65m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥2.872023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.762023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-24.322022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥3.262022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥4.792022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio57.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio56.4%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio60.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 32
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3m
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥450,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥4m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥108m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥981m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥978m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥27m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥628,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥223m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥4m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥196m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2m
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥1m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥3m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥111m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥153m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥187,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥92m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥3m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥246m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 493
ItemContextValueUnit
Operating incomePrior1YTDDuration134775000JPY
Operating incomeCurrentYTDDuration88523000JPY
Interest income noiPrior1YTDDuration378000JPY
Interest income noiCurrentYTDDuration51000JPY
Foreign exchange gains noiPrior1YTDDuration5816000JPY
Foreign exchange gains noiCurrentYTDDuration34216000JPY
Insurance income noiPrior1YTDDuration2604000JPY
Insurance income noiCurrentYTDDuration3061000JPY
Insurance premiums refunded cancellation noiPrior1YTDDuration155376000JPY
Insurance premiums refunded cancellation noiCurrentYTDDuration－JPY
Other noiPrior1YTDDuration7900000JPY
Other noiCurrentYTDDuration4490000JPY
Non operating incomePrior1YTDDuration172076000JPY
Non operating incomeCurrentYTDDuration41820000JPY
Interest expenses noePrior1YTDDuration13073000JPY
Interest expenses noeCurrentYTDDuration24297000JPY
Acquisition expenses noePrior1YTDDuration80000000JPY
Acquisition expenses noeCurrentYTDDuration－JPY
Other noePrior1YTDDuration9469000JPY
Other noeCurrentYTDDuration11254000JPY
Non operating expensesPrior1YTDDuration102543000JPY
Non operating expensesCurrentYTDDuration35552000JPY
Ordinary incomePrior1YTDDuration204309000JPY
Ordinary incomeCurrentYTDDuration94791000JPY
Impairment loss elPrior1YTDDuration47756000JPY
Impairment loss elCurrentYTDDuration－JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration－JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration708000JPY
Extraordinary lossPrior1YTDDuration47756000JPY
Extraordinary lossCurrentYTDDuration708000JPY
Income before income taxesPrior1YTDDuration156552000JPY
Income before income taxesCurrentYTDDuration94083000JPY
Income taxes currentPrior1YTDDuration8164000JPY
Income taxes currentCurrentYTDDuration32720000JPY
Income taxes deferredPrior1YTDDuration93864000JPY
Income taxes deferredCurrentYTDDuration19171000JPY
Income taxesPrior1YTDDuration102028000JPY
Income taxesCurrentYTDDuration51891000JPY
Profit lossPrior1YTDDuration54523000JPY
Profit lossCurrentYTDDuration42192000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration-367000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration-6272000JPY
Profit loss attributable to owners of parentPrior1YTDDuration54891000JPY
Profit loss attributable to owners of parentCurrentYTDDuration48464000JPY
Profit lossPrior1YTDDuration54523000JPY
Profit lossCurrentYTDDuration42192000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration747000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration21549000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration11339000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration6865000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass